Which type of data becomes most important for detecting rare adverse effects after broad patient use?

• A. Randomized trial data
• B. Observational data
• C. In vitro data
• D. Animal data

Answer: (B)

Real-world safety monitoring after broad use depends on observational data because rare adverse effects only emerge when a drug is used by large, diverse patient populations over time. Randomized trials, even well conducted, enroll relatively limited numbers of people and tend to be shorter in duration, so they often miss very infrequent harms. In vitro and animal data can raise safety concerns but cannot reliably predict how often those harms occur in humans once a medicine is widely used. Observational data—from spontaneous reports, electronic health records, registries, and population-based studies—captures how a drug performs in everyday practice across varied ages, comorbidities, and concomitant medications. This type of data is key for signal detection and estimating real-world incidence, guiding further investigation and regulatory actions when needed.